Related Experiment Video
Updated: Aug 24, 2026
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus
Ho Yeong Lim1, Miwon Ahn, Hyun Cheol Chung
1Department of Medical Oncology, Ajou University School of Medicine, Suwon, Korea.
Abstract:
Although gene therapies using tissue-specific promoters have been reported to be a promising tool for treating cancers, few studies have explored this possibility for uterine cervical cancer. MN/CA9 is a transmembrane glycoprotein that was first identified in the human cervical carcinoma cell line, HeLa. Since MN/CA9 protein is highly expressed in uterine cervical cancer tissues, but not in normal cervix, we constructed a tumor-specific replication-competent adenoviral vector utilizing MN/CA9 promoter (Ad-MN/CA9-E1a), which can replicate only in MN/CA9-expressing cells. Infection of Ad-MN/CA9-E1a to MN/CA9-positive uterine cervical cancer cells (HeLa, C-33 A and SiHa) resulted in much stronger Ad5 E1a protein expressions compared with MN/CA9-negative cells (SK-RC-29), suggesting a tissue-specific replication of this recombinant adenovirus. In vitro cytotoxicity assay revealed that the growth of MN/CA9-positive cells was significantly inhibited with 0.01-1 MOI of Ad-MN/CA9-E1a, but the growth of MN/CA9-negative cells (SK-RC-29) could only be inhibited by as many as 100 MOI. Intratumoral injection of Ad-MN/CA9-E1a effectively induced growth delay of HeLa tumors in nude mice. These results suggest that a novel replication-competent adenoviral vector mediated by MN/CA9 promoter, Ad-MN/CA9-E1a, can selectively replicate in MN/CA9-expressing tumors with cytotoxic effects and may be utilized for the treatment of uterine cervical cancer.
Insights
A novel adenoviral vector, Ad-MN/CA9-E1a, targets uterine cervical cancer by replicating specifically in tumor cells expressing MN/CA9. This vector shows significant tumor cell inhibition and growth delay, offering a promising gene therapy approach.
Area of Science:
- Oncology
- Gene Therapy
- Virology
Background:
- Gene therapy using tissue-specific promoters is a potential cancer treatment.
- Uterine cervical cancer research has limited exploration of tissue-specific promoters.
- MN/CA9 is a transmembrane glycoprotein highly expressed in cervical cancer but not normal cervix.
Purpose of the Study:
- To construct and evaluate a tumor-specific replication-competent adenoviral vector utilizing the MN/CA9 promoter for uterine cervical cancer treatment.
- To assess the selective replication and cytotoxic effects of the Ad-MN/CA9-E1a vector in MN/CA9-expressing cancer cells.
Main Methods:
- Construction of a replication-competent adenoviral vector (Ad-MN/CA9-E1a) driven by the MN/CA9 promoter.
- Testing selective viral replication in MN/CA9-positive (HeLa, C-33 A, SiHa) versus MN/CA9-negative (SK-RC-29) cells.
- In vitro cytotoxicity assays and in vivo tumor growth delay studies in nude mice.
Main Results:
- Ad-MN/CA9-E1a demonstrated significantly stronger Ad5 E1a protein expression in MN/CA9-positive cervical cancer cells compared to negative cells, indicating tissue-specific replication.
- In vitro assays showed significant inhibition of MN/CA9-positive cell growth at low multiplicities of infection (MOI), while MN/CA9-negative cells required high MOI for inhibition.
- Intratumoral injection of Ad-MN/CA9-E1a effectively delayed HeLa tumor growth in nude mice.
Conclusions:
- The Ad-MN/CA9-E1a vector selectively replicates in MN/CA9-expressing tumors.
- The vector exhibits potent cytotoxic effects against cervical cancer cells.
- Ad-MN/CA9-E1a represents a promising novel gene therapy strategy for uterine cervical cancer.
Related Concept Videos
00:59Gene Therapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...